<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6418007</article-id><article-id pub-id-type="doi">10.3389/fimmu.2019.00365</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Determining Antigen Specificity of Human Islet Infiltrating T Cells in Type 1 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nakayama</surname><given-names>Maki</given-names></name></contrib><contrib contrib-type="author"><name><surname>Michels</surname><given-names>Aaron W.</given-names></name><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/595334/overview"/></contrib></contrib-group><aff><institution>Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine</institution>, <addr-line>Aurora, CO</addr-line>, <country>United States</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Clemencia Pinilla, Torrey Pines Institute for Molecular Studies, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Anne Cooke, University of Cambridge, United Kingdom; Bruce Milne Hall, University of New South Wales, Australia</p></fn><corresp id="c001">*Correspondence: Aaron W. Michels <email>Aaron.Michels@ucdenver.edu</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to T Cell Biology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>08</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><elocation-id>365</elocation-id><history><date date-type="received"><day>14</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>2</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#169; 2019 Nakayama and Michels.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Nakayama and Michels</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Type 1 diabetes, the immune mediated form of diabetes, represents a prototypical organ specific autoimmune disease in that insulin producing pancreatic islets are specifically targeted by T cells. The disease is now predictable in humans with the measurement of type 1 diabetes associated autoantibodies (islet autoantibodies) in the peripheral blood which are directed against insulin and beta cell proteins. With an increasing incidence of disease, especially in young children, large well-controlled clinical prevention trials using antigen specific immunotherapy have been completed but with limited clinical benefit. To improve outcomes, it is critical to understand the antigen and T cell receptor repertoires of those cells that infiltrate the target organ, pancreatic islets, in human type 1 diabetes. With international networks to identify organ donors with type 1 diabetes, improved immunosequencing platforms, and the ability to reconstitute T cell receptors of interest into immortalized cell lines allows antigen discovery efforts for rare tissue specific T cells. Here we review the disease pathogenesis of type 1 diabetes with a focus on human islet infiltrating T cell antigen discovery efforts, which provides necessary knowledge to define biomarkers of disease activity and improve antigen specific immunotherapy approaches for disease prevention.</p></abstract><kwd-group><kwd>diabetes</kwd><kwd>autoimmunity</kwd><kwd>HLA</kwd><kwd>insulin</kwd><kwd>T cells</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">National Institutes of Health<named-content content-type="fundref-id">10.13039/100000002</named-content></funding-source><award-id rid="cn001">DK108868</award-id><award-id rid="cn001">DK032083</award-id><award-id rid="cn001">DK110845</award-id><award-id rid="cn001">DK099317</award-id><award-id rid="cn001">DK104223</award-id></award-group></funding-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="80"/><page-count count="7"/><word-count count="6389"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Type 1 diabetes is a chronic autoimmune disorder that results from the tissue specific destruction of insulin producing beta-cells within pancreatic islets (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). Human leukocyte antigen (HLA) genes, especially the class II DQ and DR alleles, confer significant disease risk (<xref rid="B3" ref-type="bibr">3</xref>&#8211;<xref rid="B5" ref-type="bibr">5</xref>). In addition to T1D risk genes, there are yet to be identified environment factors that lead to a loss of tolerance to insulin and other beta cell proteins. It is now appreciated that T1D develops in stages prior to the clinical onset of symptoms and these stages are defined with the presence of islet autoantibodies (<xref rid="B6" ref-type="bibr">6</xref>), those directed against insulin, glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), and zinc transporter 8 (ZnT8). From prospective birth cohort studies, if an at-risk child has two or more islet autoantibodies, there is ~85% chance of developing T1D within 15 years and a nearly 100% lifetime risk for disease development (<xref rid="B7" ref-type="bibr">7</xref>). With the ability to stage the disease process and an increasing incidence over the last two decades (<xref rid="B8" ref-type="bibr">8</xref>), a number of largescale immune intervention trials have been completed trying to delay or prevent the onset of clinical disease. Many of these trials have used formulations of insulin (subcutaneous, intranasal, oral, and intradermal) as an antigen specific therapy (<xref rid="B9" ref-type="bibr">9</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>). Unfortunately, the trials have been of limited clinical benefit and there is a need for safe and specific therapies to prevent the onset of T1D (<xref rid="B14" ref-type="bibr">14</xref>). We believe understanding the immunology within the target tissue, pancreatic islets, will lead to improved markers of disease activity and therapies to delay T1D onset (<xref rid="B15" ref-type="bibr">15</xref>). This has been challenging due to the anatomic location of the pancreas and dual function as both an exocrine and endocrine organ. However, recent efforts and advances in technology have made the study of pancreatic islets from recent onset T1D organ donors possible. Here we review the progress made in understanding the reactivity of islet infiltrating CD4 T cells with a focus on the trimolecular complex of T cell receptor&#8211;peptide&#8211;HLA molecule (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>The trimolecular complex consists of a CD4 T cell receptor&#8211;Peptide&#8211;HLA class II molecule. The peptide binding groove of the HLA class II molecule consists of pockets (P1, P4, P6, and P9) which bind amino acid side chains to anchor a peptide. The arrows of the peptide represent amino acid side chains. The T cell receptor is comprised of alpha and beta chains with three complementary determining regions (CDR) each. The T cell receptor interacts with both peptide amino acid side chains and those located on the HLA molecule to become activated.</p></caption><graphic xlink:href="fimmu-10-00365-g0001"/></fig></sec><sec id="s2"><title>Stages of T1D Development</title><p>At the current time, a significant amount of understanding surrounds the natural history of T1D development. Much of our understanding comes from both animal models of disease development and birth cohort studies that have followed genetically at-risk children (i.e., those with high risk HLA class II DQ and DR alleles) prospectively from birth to disease onset. These large epidemiology studies have taken place in the United States, Diabetes AutoImmunity Study in the Young (DAISY) (<xref rid="B16" ref-type="bibr">16</xref>), and Europe, including the Type 1 Diabetes Prediction and Prevention Study (DIPP) in Finland (<xref rid="B17" ref-type="bibr">17</xref>), and BABYDIAB studies in Germany (<xref rid="B18" ref-type="bibr">18</xref>). All three studies measured islet autoantibodies from the peripheral blood at regular time intervals (every 3&#8211;6 months) and showed that the presence of two or more islet autoantibodies marks the start of T1D, as nearly all of these genetically at risk children and adolescents develop clinical T1D, indicated by elevated blood glucose, insulin deficiency, and the need for exogenous insulin treatment. Notably, islet autoantibodies are markers of a disease state (islet autoimmunity) but not disease activity as antibodies can be present for years prior to clinical T1D presentation (<xref rid="B19" ref-type="bibr">19</xref>). The preclinical phase of T1D is now staged by the presence of islet autoantibodies and beta cell function, as measured by an oral glucose tolerance test (<xref rid="B6" ref-type="bibr">6</xref>). Stage 1 is the presence of two or more islet autoantibodies with no dysglycemia, Stage 2 encompasses those with autoantibodies and metabolic abnormalities, and Stage 3 is prototypical new-onset T1D in which an individual meets diagnostic blood glucose criteria for diabetes and the presence of islet autoantibodies (<xref rid="B20" ref-type="bibr">20</xref>). This staging paradigm leads to T1D being predictable and the ability to perform clinical intervention trials prior to a significant loss of beta cell function, with these trials previously reviewed (<xref rid="B21" ref-type="bibr">21</xref>).</p><p>Significant insights into disease pathogenesis come from the studying of animal models of autoimmune diabetes (<xref rid="B22" ref-type="bibr">22</xref>). The non-obese diabetic (NOD) mouse is a spontaneous model of autoimmune diabetes and shares many similarities with human disease (<xref rid="B23" ref-type="bibr">23</xref>). Both have major histocompatibility (MHC) class II genes that confer disease risk, NOD mice develop autoantibodies to insulin prior to hyperglycemia, and immune cells including T cells infiltrate the pancreatic islets (termed insulitis) in these mice. Disease specific T cells from the islets and pancreatic lymph nodes reveal that insulin is a critical self-antigen in the disease process (<xref rid="B24" ref-type="bibr">24</xref>&#8211;<xref rid="B29" ref-type="bibr">29</xref>). A fragment of the insulin B chain, amino acids 9-23 (B:9-23), is a CD4 T cell epitope and mutation of a single amino acid within the B chain (B16 tyrosine to alanine) results in mice maintaining normoglycemia without insulitis (<xref rid="B27" ref-type="bibr">27</xref>). This is not the case for other beta cell antigens including GAD, islet antigen 2 and glucose-6-phosphatase catalytic subunit-related protein (<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B32" ref-type="bibr">32</xref>) with the exception of chromogranin A, elimination of which results in significant protection from islet autoimmunity in NOD mice (<xref rid="B33" ref-type="bibr">33</xref>).</p><p>These insights from the NOD have translated to human disease in that insulin B:9-23 reactive T cells have been identified within the islets of recent onset organ donors and in the peripheral blood of T1D patients (<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). Notably insulin B:9-23 has an identical amino acid sequence in mouse and humans. Further support for insulin as a key self-antigen in a subset of T1D patients comes from the TEDDY study, The Environmental Determinants of Diabetes in the Young, which is an international multicenter prospective study evaluating environmental factors that may lead to the development of autoantibodies (islet autoimmunity) and eventual T1D (<xref rid="B39" ref-type="bibr">39</xref>). It is becoming appreciated that genetically at-risk children present with a different initial islet autoantibody that are correlated to HLA-DQ-DR genotypes. The presence of HLA-DR4-DQ8 haplotype (DR and DQ are in linkage disequilibrium on chromosome 6) is associated with insulin autoimmunity, while the DR3-DQ2 haplotype may reflect initial autoimmunity to GAD (<xref rid="B40" ref-type="bibr">40</xref>). These important findings indicate: (1) T1D risk genes are strongly associated with markers of an adaptive immune response to self-antigen and (2) there is disease heterogeneity such that subsets of patients may be defined by the presence of given HLA genes.</p><p>Another animal model of autoimmune diabetes that has been instrumental in understanding mechanisms of disease development is the BioBreeding rat. In these models there are diabetes prone animals that develop spontaneous islet infiltration, and separately diabetes resistant rats in which diabetes is induced with a viral infection or other stimulus of innate immune system activation (<xref rid="B41" ref-type="bibr">41</xref>). The use of an environmental trigger, such as a viral infection, may mimic an environmental exposure needed to induce human islet autoimmunity, and eventual T1D in a genetically susceptible individual.</p><p>Animal models unfortunately have not been as robust of a model for clinical therapeutics (<xref rid="B42" ref-type="bibr">42</xref>). The potential reasons for this are many, including dose, route, and timing of an intervention in the disease process. For example, antigen specific therapies tend to work well to prevent NOD diabetes onset when administered early in the disease process (e.g., before the development of insulin autoantibodies) but become less effective as the disease progresses (<xref rid="B43" ref-type="bibr">43</xref>). In contrast, anti-CD3 monoclonal antibodies are able to delay disease onset when administered later in the NOD disease course (<xref rid="B42" ref-type="bibr">42</xref>). Just as there are different animal models of T1D with spontaneous and inducible disease processes, human T1D is likely not a single disease. There is disease heterogeneity and the need exists to understand different subtypes of the condition, i.e., those that have a distinct pathophysiologic mechanism leading to T1D development (<xref rid="B44" ref-type="bibr">44</xref>), to improve the development of disease modifying therapies for T1D. As HLA class II genes confer genetic risk and function to present processed antigens to CD4 T cells, understanding this trimolecular complex (<xref ref-type="fig" rid="F1">Figure 1</xref>) within the target tissue (pancreatic islets) in human disease is critical for disease prevention and reversal (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B46" ref-type="bibr">46</xref>).</p></sec><sec id="s3"><title>Network for Pancreatic Organ Donors (nPOD)</title><p>The Network for Pancreatic Organ Donors (nPOD, <ext-link ext-link-type="uri" xlink:href="http://www.jdrfnpod.org/">http://www.jdrfnpod.org/</ext-link>) was established in 2007 to address the gap in the field to study the target organ in autoimmune T1D (<xref rid="B47" ref-type="bibr">47</xref>). Tissues from organ donors are collected and distributed to investigators for the study into the pathogenesis of human T1D. To date over 150 cases have been collected from T1D patients, over 150 non-diabetic donors and several dozens with autoantibodies but no clinical diabetes. This large and collaborative consortium has provided the frame work to study the human pancreas, islets embedded within the pancreas, pancreatic lymph nodes, and spleen in those with and without disease. Many insights have been gleaned from a decade of studies and recently reviewed (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B49" ref-type="bibr">49</xref>).</p><p>Prior to the efforts of nPOD, most of the knowledge regarding T cell reactivity came from the study of rare antigen specific cells in the peripheral blood with multiple groups cloning islet reactive T cells (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B50" ref-type="bibr">50</xref>&#8211;<xref rid="B53" ref-type="bibr">53</xref>). Outside of the peripheral blood, Kent and colleagues cloned insulin A chain reactive CD4 T cells from the pancreatic lymph nodes of an individual with established disease (<xref rid="B54" ref-type="bibr">54</xref>). However, in the last 3 years, three independent laboratories have reported on the antigen specificity of human islet derived CD4 T cells from recent onset T1D organ donors.</p></sec><sec id="s4"><title>Antigen Repertoire of Human Islet Infiltrating T Cells</title><p>In 2015, Mannering and colleagues reported the first results of cloning islet resident CD4 T cells from a deceased T1D organ donor (19 year-old with 3 years of T1D) (<xref rid="B55" ref-type="bibr">55</xref>). The donor had residual insulin staining within islets and hand-picked islets were cultured under conditions to promote T cell growth. Outgrowths of T cells were apparent and these cells were then single cell sorted using flow cytometry. Clones were established and then tested for reactivity to overlapping peptides of proinsulin and 26 peptides derived from other islet autoantigens&#8211;GAD65, IA-2, IGRP, and ZnT8. Epstein Barr Virus (EBV) transformed B cells from the donor were used as antigen presenting cells (APCs) in these T cell stimulation assays. Remarkably, 14 out of 53 tested CD4 T cell clones (26%) responded to six overlapping peptides within the C-peptide region of proinsulin (<xref rid="B55" ref-type="bibr">55</xref>) (<xref ref-type="fig" rid="F2">Figure 2</xref>). The HLA restriction element was predominantly DQ8 and one clone responded to a C-peptide fragment presented by DQ8 trans. HLA-DQ8 (DQA<sup>*</sup>03:01, DQB<sup>*</sup>03:02) is present in ~60% of all T1D patients and those at risk and confers an odds ratio for disease development of 6.5&#8211;11 (<xref rid="B3" ref-type="bibr">3</xref>). HLA-DQ2 (DQA<sup>*</sup>05:01, DQB<sup>*</sup>02:01) is also present in about 1/3 T1D patients, and trans dimers can be formed where the beta alpha chain of DQ2 pairs with the beta chain of DQ8 (DQ8 trans: DQA<sup>*</sup>05:01, DQB<sup>*</sup>03:02), which may present unique epitopes to autoreactive CD4 T cells in T1D (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B57" ref-type="bibr">57</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Amino acid sequence of human proinsulin with shaded areas representing CD4 T cell epitopes recognized by islet derived T cells. T cells obtained from the insulitis lesions of recent onset T1D organ donors respond to epitopes within the shaded area of the insulin B chain, the B:9-23 region, and C-peptide including the amino acid sequence GQVELGGG which forms a portion of hybrid insulin peptides. These islet derived T cells are predominantly activated by peptides presented by HLA-DQ8.</p></caption><graphic xlink:href="fimmu-10-00365-g0002"/></fig><p>Using a similar approach, Kent and colleagues cloned CD4 T cells from hand-picked islets of nine recent onset organ donors with T1D (<xref rid="B58" ref-type="bibr">58</xref>). In addition to growing T cell lines directly from islets, dispersed islets were stained, flow sorted for CD4 and CD8 cells and then expanded to establish <italic>ex vivo</italic> T cell lines. Fifty of the CD4 T cell lines were tested for antigen specificity using autologous EBV transformed B cells as APCs and a large panel of known or putative islet antigens including some which were post-translationally modified. Antigen specificity was identified in 17/50 (34%) of the tested T cell lines with a wide array of antigens represented including some which may represent post-translationally modified peptides (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). These T cell lines predominantly secreted inflammatory cytokines such as IFN-&#947;, TNF-&#945;, and IL-2 in response to their cognate peptide/HLA.</p><p>We used an alternate but complementary approach to study islet infiltrating T cells from three recent onset T1D organ donors, all of whom had insulitis and the T1D risk HLA-DQ8 allele (<xref rid="B37" ref-type="bibr">37</xref>). Hand-picked islets underwent short-term culture (~3&#8211;4 days) followed by single cell flow sorting for CD4 and CD8 cells. Instead of attempting to expand the single T cells, we sequenced the alpha and beta chains of the TCR of each individual cell. This provided insights into the diversity of the TCR repertoire of islet infiltrating T cells. We were able to isolate hundreds to thousands of T cells from 500 to 1,500 islet equivalents. CD8 T cells were more clonally expanded in these donors as 1/3 to 1/2 of all full length receptors were detected more than twice in the same donor (<xref rid="B37" ref-type="bibr">37</xref>). For CD4 T cells, only 15&#8211;20% of the sequences were detected more than twice from two of the donors (<xref rid="B37" ref-type="bibr">37</xref>). While none of the identical sequences were shared between the three patients, it could due to the limited number of cases studied and further efforts may reveal public TCRs shared across patients.</p><p>To test antigen specificity, the TCR sequences from CD4 T cells were transduced into an immortalized TCR null cell line, thus making a single TCR transductant, and screened against overlapping preproinsulin peptides and other characterized islet antigens derived from peripheral blood T cell reactivity of patients. These TCR transductants are readily expanded in culture and provide a robust reagent to determine antigen specificity as these cells secrete IL-2 when the TCR engages cognate peptide/HLA (<xref rid="B60" ref-type="bibr">60</xref>). From 85 selected CD4 TCR transductants, 3 responded to peptides within proinsulin (<xref rid="B37" ref-type="bibr">37</xref>). Two TCRs from two separate donors responded to insulin B:9-23 presented by DQ8 and one TCR responded to C-peptide 19-35 presented by DQ8 trans (<xref ref-type="fig" rid="F2">Figure 2</xref>). Importantly, the insulin B:9-23 responding T cells also responded to whole islets as antigen when presented by APCs bearing DQ8. Notably, reactivity to the DQ8 trans epitope within C-peptide is identical to that reported by Mannering and colleagues in a separate patient (<xref rid="B55" ref-type="bibr">55</xref>). This raises the distinct possibility that there are common epitopes within proinsulin, insulin B:9-23 and C-peptide 19-35, that stimulate islet infiltrating CD4 T cells even after the clinical onset of T1D.</p><p>Further research is underway to characterize the antigen specificity of the remaining CD4 TCR transductants and in a similar manner the CD8 T cell specificities and their HLA restriction elements. It is notable that the majority of the T cell lines, clones, and transductants reported on to date have unknown antigen specificities. Developing high or moderate throughput screening systems will aid in this endeavor. As TCR transductants are engineered T cells, these cells are amenable to fluorescent reporter systems based upon TCR stimulation, thereby providing the ability to combine multiple T cells into a single well of a stimulation assay. The use of human islet extracts as a source of antigen, including those cultured with agents that induce beta cell &#8220;stress,&#8221; may provide tools to determine mechanisms by which autoantigens are formed in various disease conditions. Finally, combinatorial peptide libraries provide another avenue to define ligands for the islet derived T cell clones, lines, and transductants which have had success in other immune mediated diseases (<xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>).</p></sec><sec id="s5"><title>Implications for Studying Tissue Specific T Cells in T1D</title><p>For T1D, understanding the specificities and antigen receptor repertoire of those T cells within the target tissue will provide novel insights into disease pathogenesis and help to further dissect disease heterogeneity. Studying tissue specific T cells also provides an avenue to develop biomarkers to assess disease activity and monitoring immune responses to therapies. Islet autoantibodies mark a disease state in which the adaptive immune response has targeted pancreatic islets; however, these do not correlate to disease activity (i.e., insulitis and beta cell destruction). Conversely, T cells can cause tissue specific destruction and may provide markers of an active disease state, especially those cells that circulate in the peripheral blood. Of note, insulin B:9-23 reactivity has been detected in the islets of multiple T1D organ donors and peripheral blood of T1D patients (<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>). Further understanding the TCR repertoires across patients holds potential for developing a non-cell based biomarker assay as compared to traditional assays using fluorescent multimers (<xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>) and functional assays such as cytokine enzyme linked ImmunoSpot (ELISPOT) (<xref rid="B65" ref-type="bibr">65</xref>, <xref rid="B66" ref-type="bibr">66</xref>). As immunosequencing technologies continue to advance, combined with machine learning algorithms, the potential exists to understand clonally expanded TCR repertoires and their ligands in disease states (<xref rid="B67" ref-type="bibr">67</xref>).</p><p>One of the major goals of studying human islet infiltrating T cells is to apply this knowledge to the development of therapies to prevent disease onset, induce tissue specific tolerance, and ultimately reverse the disease process. As mentioned previously, T1D does not represent a single disease pathogenesis and there are likely different mechanisms or pathways which lead to the immune system losing tolerance to insulin producing beta cells (<xref rid="B44" ref-type="bibr">44</xref>). It is important to understand these pathways and identify the different patient subsets or endotypes who share similar features to improve disease modifying therapies within T1D.</p><p>Antigen specific therapy has long held promise to both delete effector T cells and induce regulatory T cells to self-antigens (<xref rid="B68" ref-type="bibr">68</xref>). By understanding T cell reactivity within human T1D islets, it is our belief that antigen specific therapy can be better designed and subsets of patients identified with these T cell responses in their peripheral blood. It is conceivable that whole antigens (e.g., preproinsulin) or multiple relevant peptides need to be administered to patients with these reactivities. For example, a subset of patients may have dominant T cell responses directed toward insulin epitopes and benefit to proinsulin based antigen therapies, while other patients may have predominant GAD reactivity and would respond to GAD based antigen therapies. This rationale is in line with the findings from TEDDY indicating that a subset of children present with initial insulin autoimmunity or GAD autoimmunity based upon HLA genotype (<xref rid="B40" ref-type="bibr">40</xref>). An important caveat to mention is the fact that combination therapy will likely be needed based upon the stage of T1D treated (<xref rid="B14" ref-type="bibr">14</xref>). At new-onset T1D (Stage 3) induction therapy could be followed by antigen specific therapy in an attempt to induce antigen specific tolerance. Induction therapies could include a monoclonal antibody directed against CD2 or CD3 on T cells (<xref rid="B69" ref-type="bibr">69</xref>&#8211;<xref rid="B72" ref-type="bibr">72</xref>), CD20 on B cells (<xref rid="B73" ref-type="bibr">73</xref>), CD80/86 on APCs (<xref rid="B74" ref-type="bibr">74</xref>), or polyclonal anti-thymocyte globuliln (ATG) (<xref rid="B75" ref-type="bibr">75</xref>), which have all shown short-term ability to preserve residual beta cell function in clinical trials with new-onset T1D patients.</p><p>Another promising disease modifying therapy uses small &#8220;druglike&#8221; molecules to block self-antigens presented by HLA-DQ8 (<xref rid="B76" ref-type="bibr">76</xref>, <xref rid="B77" ref-type="bibr">77</xref>). DQ8 is common in T1D, confers significant genetic risk and is actively involved in disease pathogenesis as the vast majority of islet derived CD4 T cells studied to date are activated by proinsulin peptides presented by DQ8 (<xref rid="B58" ref-type="bibr">58</xref>). Methyldopa (Aldomet), a clinically well-established oral medication used to treat hypertension in children and adults for &gt;50 years (<xref rid="B78" ref-type="bibr">78</xref>), was discovered to bind the antigen-binding cleft of DQ8, and block peptide presentation and subsequent T cell activation to self-antigens (insulin and &#945;-gliadin) (<xref rid="B77" ref-type="bibr">77</xref>). Remarkably, methyldopa did not alter a T cell response to an influenza epitope presented by DQ8. In a proof of concept clinical trial, recent onset T1D patients were genetically selected for DQ8 and administered methyldopa (<ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">www.clinicaltrials.gov</ext-link> NCT01883804). Methyldopa specifically blocked DQ8, not DR4 or DQ2, in these patients and lessened the inflammatory response of insulin specific T cells (<xref rid="B77" ref-type="bibr">77</xref>). As many autoimmune diseases are associated with specific HLA class II genes (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B80" ref-type="bibr">80</xref>), genetically selecting patients and treating with drugs to block self-antigen T cell activation by these HLA molecules has broad applicability to treating not only T1D but other autoimmune diseases.</p></sec><sec sec-type="conclusions" id="s6"><title>Conclusions</title><p>There is a need to study T cells within the target tissue, pancreatic islets, of T1D patients. This need is being met through collaborative research efforts such as the Network for Pancreatic Organ Donors (nPOD). Findings from independent laboratories are defining the components of the trimolecular complex, TCR-peptide-HLA, within human islet infiltrating CD4 T cells. This understanding provides a framework to understand disease heterogeneity and develop biomarkers of disease activity, which hold promise for disease monitoring and timing of therapeutic interventions. Ultimately, this understanding will aid in the design and development of improved therapies aimed at inducing tolerance to islet antigens and preventing T1D onset.</p></sec><sec id="s7"><title>Author Contributions</title><p>MN and AM both wrote and edited the manuscript.</p><sec><title>Conflict of Interest Statement</title><p>AM and MN are inventors on an issued patent, Compounds That Modulate Autoimmunity and Methods of Using the Same, licensed to ImmunoMolecular Therapeutics, LLC. AM is a scientific cofounder of ImmunoMolecular Therapeutics.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by grants from the National Institutes of Health (DK108868, DK032083, DK110845, DK099317, and DK104223), Juvenile Diabetes Research Foundation, and the Children's Diabetes Foundation.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bluestone</surname><given-names>JA</given-names></name><name><surname>Herold</surname><given-names>K</given-names></name><name><surname>Eisenbarth</surname><given-names>G</given-names></name></person-group>. <article-title>Genetics, pathogenesis and clinical interventions in type 1 diabetes</article-title>. <source>Nature.</source> (<year>2010</year>) <volume>464</volume>:<fpage>1293</fpage>&#8211;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1038/nature08933</pub-id><?supplied-pmid 20432533?><pub-id pub-id-type="pmid">20432533</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkinson</surname><given-names>MA</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Michels</surname><given-names>AW</given-names></name></person-group>. <article-title>Type 1 diabetes</article-title>. <source>Lancet.</source> (<year>2014</year>) <volume>383</volume>:<fpage>69</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60591-7</pub-id><?supplied-pmid 23890997?><pub-id pub-id-type="pmid">23890997</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erlich</surname><given-names>H</given-names></name><name><surname>Valdes</surname><given-names>AM</given-names></name><name><surname>Noble</surname><given-names>J</given-names></name><name><surname>Carlson</surname><given-names>JA</given-names></name><name><surname>Varney</surname><given-names>M</given-names></name><name><surname>Concannon</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families</article-title>. <source>Diabetes.</source> (<year>2008</year>) <volume>57</volume>:<fpage>1084</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.2337/db07-1331</pub-id><?supplied-pmid 18252895?><pub-id pub-id-type="pmid">18252895</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concannon</surname><given-names>P</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Nepom</surname><given-names>GT</given-names></name></person-group>. <article-title>Genetics of type 1A diabetes</article-title>. <source>N Engl J Med.</source> (<year>2009</year>) <volume>360</volume>:<fpage>1646</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra0808284</pub-id><?supplied-pmid 19369670?><pub-id pub-id-type="pmid">19369670</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Deutsch</surname><given-names>AJ</given-names></name><name><surname>Lenz</surname><given-names>TL</given-names></name><name><surname>Onengut-Gumuscu</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><etal/></person-group>. <article-title>Additive and interaction effects at three amino acid positions in HLA-DQ and HLA-DR molecules drive type 1 diabetes risk</article-title>. <source>Nat Genet.</source> (<year>2015</year>) <volume>47</volume>:<fpage>898</fpage>&#8211;<lpage>905</lpage>. <pub-id pub-id-type="doi">10.1038/ng.3353</pub-id><?supplied-pmid 26168013?><pub-id pub-id-type="pmid">26168013</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Semenkovich</surname><given-names>CF</given-names></name><name><surname>Danska</surname><given-names>J</given-names></name><name><surname>Darsow</surname><given-names>T</given-names></name><name><surname>Dunne</surname><given-names>JL</given-names></name><name><surname>Huttenhower</surname><given-names>C</given-names></name><name><surname>Insel</surname><given-names>RA</given-names></name><etal/></person-group>. <article-title>American Diabetes association and JDRF research symposium: diabetes and the microbiome</article-title>. <source>Diabetes.</source> (<year>2015</year>) <volume>64</volume>:<fpage>3967</fpage>&#8211;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.2337/db15-0597</pub-id><?supplied-pmid 26420863?><pub-id pub-id-type="pmid">26420863</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Rewers</surname><given-names>M</given-names></name><name><surname>Simell</surname><given-names>O</given-names></name><name><surname>Simell</surname><given-names>T</given-names></name><name><surname>Lempainen</surname><given-names>J</given-names></name><name><surname>Steck</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children</article-title>. <source>JAMA.</source> (<year>2013</year>) <volume>309</volume>:<fpage>2473</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.6285</pub-id><?supplied-pmid 23780460?><pub-id pub-id-type="pmid">23780460</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Davis</surname><given-names>EJ</given-names></name><name><surname>Lawrence</surname><given-names>JM</given-names></name><name><surname>Dabelea</surname><given-names>D</given-names></name><name><surname>Divers</surname><given-names>J</given-names></name><name><surname>Isom</surname><given-names>S</given-names></name><name><surname>Dolan</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012</article-title>. <source>N Engl J Med.</source> (<year>2017</year>) <volume>376</volume>:<fpage>1419</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1610187</pub-id><?supplied-pmid 28402773?><pub-id pub-id-type="pmid">28402773</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Diabetes Prevention Trial&#8211;Type 1 Diabetes Study Group</collab></person-group>
<article-title>Effects of insulin in relatives of patients with type 1 diabetes mellitus</article-title>. <source>N Engl J Med.</source> (<year>2002</year>) <volume>346</volume>:<fpage>1685</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa012350</pub-id><pub-id pub-id-type="pmid">12037147</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyler</surname><given-names>JS</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Wolfsdorf</surname><given-names>J</given-names></name><name><surname>Cowie</surname><given-names>C</given-names></name><name><surname>Palmer</surname><given-names>JP</given-names></name><name><surname>Greenbaum</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes Prevention Trial&#8211;Type 1</article-title>. <source>Diabetes Care.</source> (<year>2005</year>) <volume>28</volume>:<fpage>1068</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.28.5.1068</pub-id><?supplied-pmid 15855569?><pub-id pub-id-type="pmid">15855569</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanto-Salonen</surname><given-names>K</given-names></name><name><surname>Kupila</surname><given-names>A</given-names></name><name><surname>Simell</surname><given-names>S</given-names></name><name><surname>Siljander</surname><given-names>H</given-names></name><name><surname>Salonsaari</surname><given-names>T</given-names></name><name><surname>Hekkala</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial</article-title>. <source>Lancet.</source> (<year>2008</year>) <volume>372</volume>:<fpage>1746</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(08)61309-4</pub-id><?supplied-pmid 18814906?><pub-id pub-id-type="pmid">18814906</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alhadj Ali</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name><name><surname>Arif</surname><given-names>S</given-names></name><name><surname>Tatovic</surname><given-names>D</given-names></name><name><surname>Shariff</surname><given-names>H</given-names></name><name><surname>Gibson</surname><given-names>VB</given-names></name><etal/></person-group>. <article-title>Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes</article-title>. <source>Sci Transl Med.</source> (<year>2017</year>) <volume>9</volume>:<fpage>eaaf7779</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.aaf7779</pub-id><?supplied-pmid 28794283?><pub-id pub-id-type="pmid">28794283</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Bundy</surname><given-names>B</given-names></name><name><surname>Skyler</surname><given-names>JS</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name></person-group>. <article-title>Effect of oral insulin on prevention of diabetes in relatives of patients with type 1 diabetes: a randomized clinical trial</article-title>. <source>JAMA.</source> (<year>2017</year>) <volume>318</volume>:<fpage>1891</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2017.17070</pub-id><?supplied-pmid 29164254?><pub-id pub-id-type="pmid">29164254</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skyler</surname><given-names>JS</given-names></name></person-group>. <article-title>Prevention and reversal of type 1 diabetes&#8211;past challenges and future opportunities</article-title>. <source>Diabetes Care.</source> (<year>2015</year>) <volume>38</volume>:<fpage>997</fpage>&#8211;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.2337/dc15-0349</pub-id><?supplied-pmid 25998292?><pub-id pub-id-type="pmid">25998292</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Simmons</surname><given-names>KM</given-names></name><name><surname>Michels</surname><given-names>AW</given-names></name></person-group>. <article-title>Molecular interactions governing autoantigen presentation in type 1 diabetes</article-title>. <source>Curr Diab Rep.</source> (<year>2015</year>) <volume>15</volume>:<fpage>113</fpage>. <pub-id pub-id-type="doi">10.1007/s11892-015-0689-z</pub-id><?supplied-pmid 26458384?><pub-id pub-id-type="pmid">26458384</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>JM</given-names></name><name><surname>Barriga</surname><given-names>KJ</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Erlich</surname><given-names>HA</given-names></name><name><surname>Norris</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY)</article-title>. <source>J Clin Endocrinol Metab.</source> (<year>2004</year>) <volume>89</volume>:<fpage>3896</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2003-031887</pub-id><?supplied-pmid 15292324?><pub-id pub-id-type="pmid">15292324</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kupila</surname><given-names>A</given-names></name><name><surname>Keskinen</surname><given-names>P</given-names></name><name><surname>Simell</surname><given-names>T</given-names></name><name><surname>Erkkila</surname><given-names>S</given-names></name><name><surname>Arvilommi</surname><given-names>P</given-names></name><name><surname>Korhonen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Genetic risk determines the emergence of diabetes-associated autoantibodies in young children</article-title>. <source>Diabetes.</source> (<year>2002</year>) <volume>51</volume>:<fpage>646</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.51.3.646</pub-id><?supplied-pmid 11872662?><pub-id pub-id-type="pmid">11872662</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Hummel</surname><given-names>M</given-names></name><name><surname>Schenker</surname><given-names>M</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name></person-group>. <article-title>Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study</article-title>. <source>Diabetes.</source> (<year>1999</year>) <volume>48</volume>:<fpage>460</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.48.3.460</pub-id><?supplied-pmid 10078544?><pub-id pub-id-type="pmid">10078544</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonifacio</surname><given-names>E</given-names></name></person-group>. <article-title>Predicting type 1 diabetes using biomarkers</article-title>. <source>Diabetes Care.</source> (<year>2015</year>) <volume>38</volume>:<fpage>989</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.2337/dc15-0101</pub-id><?supplied-pmid 25998291?><pub-id pub-id-type="pmid">25998291</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>
<article-title>Classification and diagnosis of diabetes: standards of medical care in diabetes-2018</article-title>. <source>Diabetes Care.</source> (<year>2018</year>) <volume>41</volume>(<issue>Suppl. 1</issue>):<fpage>S13</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.2337/dc18-S002</pub-id><pub-id pub-id-type="pmid">29222373</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>KM</given-names></name><name><surname>Gottlieb</surname><given-names>PA</given-names></name><name><surname>Michels</surname><given-names>AW</given-names></name></person-group>. <article-title>Immune Intervention and preservation of pancreatic beta cell function in type 1 diabetes</article-title>. <source>Curr Diab Rep.</source> (<year>2016</year>) <volume>16</volume>:<fpage>97</fpage>. <pub-id pub-id-type="doi">10.1007/s11892-016-0793-8</pub-id><?supplied-pmid 27558810?><pub-id pub-id-type="pmid">27558810</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaparro</surname><given-names>RJ</given-names></name><name><surname>Dilorenzo</surname><given-names>TP</given-names></name></person-group>. <article-title>An update on the use of NOD mice to study autoimmune (Type 1) diabetes</article-title>. <source>Expert Rev Clin Immunol.</source> (<year>2010</year>) <volume>6</volume>:<fpage>939</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1586/eci.10.68</pub-id><?supplied-pmid 20979558?><pub-id pub-id-type="pmid">20979558</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driver</surname><given-names>JP</given-names></name><name><surname>Serreze</surname><given-names>DV</given-names></name><name><surname>Chen</surname><given-names>YG</given-names></name></person-group>. <article-title>Mouse models for the study of autoimmune type 1 diabetes: a NOD to similarities and differences to human disease</article-title>. <source>Semin Immunopathol.</source> (<year>2011</year>) <volume>33</volume>:<fpage>67</fpage>&#8211;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-010-0204-1</pub-id><?supplied-pmid 20424843?><pub-id pub-id-type="pmid">20424843</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daniel</surname><given-names>D</given-names></name><name><surname>Gill</surname><given-names>RG</given-names></name><name><surname>Schloot</surname><given-names>N</given-names></name><name><surname>Wegmann</surname><given-names>D</given-names></name></person-group>. <article-title>Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice</article-title>. <source>Eur J Immunol.</source> (<year>1995</year>) <volume>25</volume>:<fpage>1056</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1002/eji.1830250430</pub-id><?supplied-pmid 7537670?><pub-id pub-id-type="pmid">7537670</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>French</surname><given-names>MB</given-names></name><name><surname>Allison</surname><given-names>J</given-names></name><name><surname>Cram</surname><given-names>DS</given-names></name><name><surname>Thomas</surname><given-names>HE</given-names></name><name><surname>Dempsey-Collier</surname><given-names>M</given-names></name><name><surname>Silva</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice</article-title>. <source>Diabetes.</source> (<year>1997</year>) <volume>46</volume>:<fpage>34</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2337/diab.46.1.34</pub-id><?supplied-pmid 8971078?><pub-id pub-id-type="pmid">8971078</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaeckel</surname><given-names>E</given-names></name><name><surname>Lipes</surname><given-names>MA</given-names></name><name><surname>von Boehmer</surname><given-names>H</given-names></name></person-group>
<article-title>Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes</article-title>. <source>Nat Immunol.</source> (<year>2004</year>) <volume>5</volume>:<fpage>1028</fpage>&#8211;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/ni1120</pub-id><pub-id pub-id-type="pmid">15378058</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Abiru</surname><given-names>N</given-names></name><name><surname>Moriyama</surname><given-names>H</given-names></name><name><surname>Babaya</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice</article-title>. <source>Nature.</source> (<year>2005</year>) <volume>435</volume>:<fpage>220</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/nature03523</pub-id><?supplied-pmid 15889095?><pub-id pub-id-type="pmid">15889095</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadinski</surname><given-names>BD</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Marrack</surname><given-names>P</given-names></name><name><surname>Eisenbarth</surname><given-names>GS</given-names></name><name><surname>Kappler</surname><given-names>JW</given-names></name></person-group>. <article-title>Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2010</year>) <volume>107</volume>:<fpage>10978</fpage>&#8211;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1006545107</pub-id><?supplied-pmid 20534455?><pub-id pub-id-type="pmid">20534455</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Stadinski</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Michels</surname><given-names>A</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Pratt</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Specificity and detection of insulin-reactive CD4+ T cells in type 1 diabetes in the nonobese diabetic (NOD) mouse</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2011</year>) <volume>108</volume>:<fpage>16729</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1113954108</pub-id><?supplied-pmid 21949373?><pub-id pub-id-type="pmid">21949373</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubosaki</surname><given-names>A</given-names></name><name><surname>Miura</surname><given-names>J</given-names></name><name><surname>Notkins</surname><given-names>AL</given-names></name></person-group>
<article-title>IA-2 is not required for the development of diabetes in NOD mice</article-title>. <source>Diabetologia.</source> (<year>2004</year>) <volume>47</volume>:<fpage>149</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-003-1252-z</pub-id><pub-id pub-id-type="pmid">14614561</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Yamato</surname><given-names>E</given-names></name><name><surname>Tashiro</surname><given-names>F</given-names></name><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Noso</surname><given-names>S</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Development of autoimmune diabetes in glutamic acid decarboxylase 65 (GAD65) knockout NOD mice</article-title>. <source>Diabetologia.</source> (<year>2004</year>) <volume>47</volume>:<fpage>221</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-003-1296-0</pub-id><?supplied-pmid 14676944?><pub-id pub-id-type="pmid">14676944</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnamurthy</surname><given-names>B</given-names></name><name><surname>Dudek</surname><given-names>NL</given-names></name><name><surname>McKenzie</surname><given-names>MD</given-names></name><name><surname>Purcell</surname><given-names>AW</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><name><surname>Gellert</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP</article-title>. <source>J Clin Invest.</source> (<year>2006</year>) <volume>116</volume>:<fpage>3258</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1172/JCI29602</pub-id><pub-id pub-id-type="pmid">17143333</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>RL</given-names></name><name><surname>Bradley</surname><given-names>B</given-names></name><name><surname>Wiles</surname><given-names>TA</given-names></name><name><surname>Lindsay</surname><given-names>RS</given-names></name><name><surname>Barbour</surname><given-names>G</given-names></name><name><surname>Delong</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cutting edge: nonobese diabetic mice deficient in chromogranin a are protected from autoimmune diabetes</article-title>. <source>J Immunol.</source> (<year>2016</year>) <volume>196</volume>:<fpage>39</fpage>&#8211;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1501190</pub-id><?supplied-pmid 26608914?><pub-id pub-id-type="pmid">26608914</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alleva</surname><given-names>DG</given-names></name><name><surname>Crowe</surname><given-names>PD</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Kwok</surname><given-names>WW</given-names></name><name><surname>Ling</surname><given-names>N</given-names></name><name><surname>Gottschalk</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin</article-title>. <source>J Clin Invest.</source> (<year>2001</year>) <volume>107</volume>:<fpage>173</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1172/JCI8525</pub-id><?supplied-pmid 11160133?><pub-id pub-id-type="pmid">11160133</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Chow</surname><given-names>IT</given-names></name><name><surname>Sosinowski</surname><given-names>T</given-names></name><name><surname>Torres-Chinn</surname><given-names>N</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><name><surname>James</surname><given-names>EA</given-names></name><etal/></person-group>. <article-title>Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2014</year>) <volume>111</volume>:<fpage>14840</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1416864111</pub-id><?supplied-pmid 25267644?><pub-id pub-id-type="pmid">25267644</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>McDaniel</surname><given-names>K</given-names></name><name><surname>Fitzgerald-Miller</surname><given-names>L</given-names></name><name><surname>Kiekhaefer</surname><given-names>C</given-names></name><name><surname>Snell-Bergeon</surname><given-names>JK</given-names></name><name><surname>Davidson</surname><given-names>HW</given-names></name><etal/></person-group>. <article-title>Regulatory vs. inflammatory cytokine T-cell responses to mutated insulin peptides in healthy and type 1 diabetic subjects</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2015</year>) <volume>112</volume>:<fpage>4429</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1502967112</pub-id><?supplied-pmid 25831495?><pub-id pub-id-type="pmid">25831495</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>AW</given-names></name><name><surname>Landry</surname><given-names>LG</given-names></name><name><surname>McDaniel</surname><given-names>KA</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Campbell-Thompson</surname><given-names>M</given-names></name><name><surname>Kwok</surname><given-names>WW</given-names></name><etal/></person-group>. <article-title>Islet-Derived CD4 T cells targeting proinsulin in human autoimmune diabetes</article-title>. <source>Diabetes.</source> (<year>2017</year>) <volume>66</volume>:<fpage>722</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.2337/db16-1025</pub-id><?supplied-pmid 27920090?><pub-id pub-id-type="pmid">27920090</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spanier</surname><given-names>JA</given-names></name><name><surname>Sahli</surname><given-names>NL</given-names></name><name><surname>Wilson</surname><given-names>JC</given-names></name><name><surname>Martinov</surname><given-names>T</given-names></name><name><surname>Dileepan</surname><given-names>T</given-names></name><name><surname>Burrack</surname><given-names>AL</given-names></name><etal/></person-group>. <article-title>Increased effector memory insulin-specific CD4(+) T cells correlate with insulin autoantibodies in patients with recent-onset type 1 diabetes</article-title>. <source>Diabetes.</source> (<year>2017</year>) <volume>66</volume>:<fpage>3051</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.2337/db17-0666</pub-id><?supplied-pmid 28842400?><pub-id pub-id-type="pmid">28842400</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steck</surname><given-names>AK</given-names></name><name><surname>Vehik</surname><given-names>K</given-names></name><name><surname>Bonifacio</surname><given-names>E</given-names></name><name><surname>Lernmark</surname><given-names>A</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><etal/></person-group>. <article-title>Predictors of progression from the appearance of islet autoantibodies to early childhood diabetes: The Environmental Determinants of Diabetes in the Young (TEDDY)</article-title>. <source>Diabetes Care.</source> (<year>2015</year>) <volume>38</volume>:<fpage>808</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.2337/dc14-2426</pub-id><?supplied-pmid 25665818?><pub-id pub-id-type="pmid">25665818</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Lynch</surname><given-names>KF</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Ilonen</surname><given-names>J</given-names></name><name><surname>Lernmark</surname><given-names>A</given-names></name><name><surname>Hagopian</surname><given-names>WA</given-names></name><etal/></person-group>. <article-title>The 6 year incidence of diabetes-associated autoantibodies in genetically at-risk children: the TEDDY study</article-title>. <source>Diabetologia.</source> (<year>2015</year>) <volume>58</volume>:<fpage>980</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-015-3514-y</pub-id><?supplied-pmid 25660258?><pub-id pub-id-type="pmid">25660258</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bortell</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group>. <article-title>The BB rat as a model of human type 1 diabetes</article-title>. <source>Methods Mol Biol.</source> (<year>2012</year>) <volume>933</volume>:<fpage>31</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-62703-068-7_3</pub-id><?supplied-pmid 22893399?><pub-id pub-id-type="pmid">22893399</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>JC</given-names></name><name><surname>Herold</surname><given-names>KC</given-names></name></person-group>. <article-title>Thinking bedside at the bench: the NOD mouse model of T1DM</article-title>. <source>Nat Rev Endocrinol.</source> (<year>2015</year>) <volume>11</volume>:<fpage>308</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/nrendo.2014.236</pub-id><?supplied-pmid 25623120?><pub-id pub-id-type="pmid">25623120</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coppieters</surname><given-names>KT</given-names></name><name><surname>Harrison</surname><given-names>LC</given-names></name><name><surname>von Herrath</surname><given-names>MG</given-names></name></person-group>. <article-title>Trials in type 1 diabetes: Antigen-specific therapies</article-title>. <source>Clin Immunol.</source> (<year>2013</year>) <volume>149</volume>:<fpage>345</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2013.02.002</pub-id><?supplied-pmid 23490422?><pub-id pub-id-type="pmid">23490422</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arif</surname><given-names>S</given-names></name><name><surname>Leete</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>V</given-names></name><name><surname>Marks</surname><given-names>K</given-names></name><name><surname>Nor</surname><given-names>NM</given-names></name><name><surname>Estorninho</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Blood and islet phenotypes indicate immunological heterogeneity in type 1 diabetes</article-title>. <source>Diabetes.</source> (<year>2014</year>) <volume>63</volume>:<fpage>3835</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.2337/db14-0365</pub-id><?supplied-pmid 24939426?><pub-id pub-id-type="pmid">24939426</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>AW</given-names></name></person-group>. <article-title>Targeting the trimolecular complex</article-title>. <source>Clin Immunol.</source> (<year>2013</year>) <volume>149</volume>:<fpage>339</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2013.02.020</pub-id><?supplied-pmid 23537861?><pub-id pub-id-type="pmid">23537861</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>AW</given-names></name></person-group>. <article-title>Targeting the trimolecular complex: the pathway towards type 1 diabetes prevention</article-title>. <source>Diabetes Technol Ther.</source> (<year>2013</year>) <volume>15</volume> (<issue>Suppl. 2</issue>):<fpage>S2-8</fpage>&#8211;<lpage>s2-12</lpage>. <pub-id pub-id-type="doi">10.1089/dia.2013.0114</pub-id><?supplied-pmid 23786298?><pub-id pub-id-type="pmid">23786298</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pugliese</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Kusmarteva</surname><given-names>I</given-names></name><name><surname>Heiple</surname><given-names>T</given-names></name><name><surname>Vendrame</surname><given-names>F</given-names></name><name><surname>Wasserfall</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The juvenile diabetes research foundation network for pancreatic organ donors with diabetes (nPOD) Program: goals, operational model and emerging findings</article-title>. <source>Pediatr Diabetes.</source> (<year>2014</year>) <volume>15</volume>:<fpage>1</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/pedi.12097</pub-id><?supplied-pmid 24325575?><pub-id pub-id-type="pmid">24325575</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaddis</surname><given-names>JS</given-names></name><name><surname>Pugliese</surname><given-names>A</given-names></name><name><surname>Atkinson</surname><given-names>MA</given-names></name></person-group>. <article-title>A run on the biobank: what have we learned about type 1 diabetes from the nPOD tissue repository?</article-title>
<source>Curr Opin Endocrinol Diabetes Obes.</source> (<year>2015</year>) <volume>22</volume>:<fpage>290</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1097/MED.0000000000000171</pub-id><?supplied-pmid 26087339?><pub-id pub-id-type="pmid">26087339</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>SC</given-names></name><name><surname>Mannering</surname><given-names>SI</given-names></name><name><surname>Michels</surname><given-names>AW</given-names></name><name><surname>Babon</surname><given-names>JAB</given-names></name></person-group>
<article-title>Deciphering the pathogenesis of human Type 1 Diabetes (T1D) by interrogating T cells from the &#8220;scene of the crime</article-title>.&#8221; <source>Curr Diab Rep.</source> (<year>2017</year>) <volume>17</volume>:<fpage>95</fpage>
<pub-id pub-id-type="doi">10.1007/s11892-017-0915-y</pub-id><pub-id pub-id-type="pmid">28864875</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallone</surname><given-names>R</given-names></name><name><surname>Kochik</surname><given-names>SA</given-names></name><name><surname>Laughlin</surname><given-names>EM</given-names></name><name><surname>Gersuk</surname><given-names>VH</given-names></name><name><surname>Reijonen</surname><given-names>H</given-names></name><name><surname>Kwok</surname><given-names>WW</given-names></name><etal/></person-group>. <article-title>Differential recognition and activation thresholds in human autoreactive GAD-specific T-cells</article-title>. <source>Diabetes.</source> (<year>2004</year>) <volume>53</volume>:<fpage>971</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2337/diabetes.53.4.971</pub-id><?supplied-pmid 15047612?><pub-id pub-id-type="pmid">15047612</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mannering</surname><given-names>SI</given-names></name><name><surname>Harrison</surname><given-names>LC</given-names></name><name><surname>Williamson</surname><given-names>NA</given-names></name><name><surname>Morris</surname><given-names>JS</given-names></name><name><surname>Thearle</surname><given-names>DJ</given-names></name><name><surname>Jensen</surname><given-names>KP</given-names></name><etal/></person-group>. <article-title>The insulin A-chain epitope recognized by human T cells is posttranslationally modified</article-title>. <source>J Exp Med.</source> (<year>2005</year>) <volume>202</volume>:<fpage>1191</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20051251</pub-id><?supplied-pmid 16260488?><pub-id pub-id-type="pmid">16260488</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>TP</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name><name><surname>Roep</surname><given-names>BO</given-names></name></person-group>. <article-title>Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes</article-title>. <source>Clin Exp Immunol.</source> (<year>2007</year>) <volume>148</volume>:<fpage>1</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2006.03244.x</pub-id><?supplied-pmid 17349009?><pub-id pub-id-type="pmid">17349009</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eerligh</surname><given-names>P</given-names></name><name><surname>van Lummel</surname><given-names>M</given-names></name><name><surname>Zaldumbide</surname><given-names>A</given-names></name><name><surname>Moustakas</surname><given-names>AK</given-names></name><name><surname>Duinkerken</surname><given-names>G</given-names></name><name><surname>Bondinas</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Functional consequences of HLA-DQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes</article-title>. <source>Genes Immun.</source> (<year>2011</year>) <volume>12</volume>:<fpage>415</fpage>&#8211;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1038/gene.2011.24</pub-id><?supplied-pmid 21562577?><pub-id pub-id-type="pmid">21562577</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kent</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Bregoli</surname><given-names>L</given-names></name><name><surname>Clemmings</surname><given-names>SM</given-names></name><name><surname>Kenyon</surname><given-names>NS</given-names></name><name><surname>Ricordi</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope</article-title>. <source>Nature.</source> (<year>2005</year>) <volume>435</volume>:<fpage>224</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature03625</pub-id><?supplied-pmid 15889096?><pub-id pub-id-type="pmid">15889096</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pathiraja</surname><given-names>V</given-names></name><name><surname>Kuehlich</surname><given-names>JP</given-names></name><name><surname>Campbell</surname><given-names>PD</given-names></name><name><surname>Krishnamurthy</surname><given-names>B</given-names></name><name><surname>Loudovaris</surname><given-names>T</given-names></name><name><surname>Coates</surname><given-names>PT</given-names></name><etal/></person-group>. <article-title>Proinsulin-specific, HLA-DQ8, and HLA-DQ8-transdimer-restricted CD4+ T cells infiltrate islets in type 1 diabetes</article-title>. <source>Diabetes.</source> (<year>2015</year>) <volume>64</volume>:<fpage>172</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.2337/db14-0858</pub-id><?supplied-pmid 25157096?><pub-id pub-id-type="pmid">25157096</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koeleman</surname><given-names>BP</given-names></name><name><surname>Lie</surname><given-names>BA</given-names></name><name><surname>Undlien</surname><given-names>DE</given-names></name><name><surname>Dudbridge</surname><given-names>F</given-names></name><name><surname>Thorsby</surname><given-names>E</given-names></name><name><surname>de Vries</surname><given-names>RR</given-names></name><etal/></person-group>. <article-title>Genotype effects and epistasis in type 1 diabetes and HLA-DQ trans dimer associations with disease</article-title>. <source>Genes Immun.</source> (<year>2004</year>) <volume>5</volume>:<fpage>381</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/sj.gene.6364106</pub-id><?supplied-pmid 15164102?><pub-id pub-id-type="pmid">15164102</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Lummel</surname><given-names>M</given-names></name><name><surname>van Veelen</surname><given-names>PA</given-names></name><name><surname>Zaldumbide</surname><given-names>A</given-names></name><name><surname>de Ru</surname><given-names>A</given-names></name><name><surname>Janssen</surname><given-names>GM</given-names></name><name><surname>Moustakas</surname><given-names>AK</given-names></name><etal/></person-group>. <article-title>Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire</article-title>. <source>J Biol Chem.</source> (<year>2012</year>) <volume>287</volume>:<fpage>9514</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.313940</pub-id><?supplied-pmid 22184118?><pub-id pub-id-type="pmid">22184118</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babon</surname><given-names>JA</given-names></name><name><surname>DeNicola</surname><given-names>ME</given-names></name><name><surname>Blodgett</surname><given-names>DM</given-names></name><name><surname>Crevecoeur</surname><given-names>I</given-names></name><name><surname>Buttrick</surname><given-names>TS</given-names></name><name><surname>Maehr</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Analysis of self-antigen specificity of islet-infiltrating T cells from human donors with type 1 diabetes</article-title>. <source>Nat Med.</source> (<year>2016</year>) <volume>22</volume>:<fpage>1482</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4203</pub-id><?supplied-pmid 27798614?><pub-id pub-id-type="pmid">27798614</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delong</surname><given-names>T</given-names></name><name><surname>Wiles</surname><given-names>TA</given-names></name><name><surname>Baker</surname><given-names>RL</given-names></name><name><surname>Bradley</surname><given-names>B</given-names></name><name><surname>Barbour</surname><given-names>G</given-names></name><name><surname>Reisdorph</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion</article-title>. <source>Science.</source> (<year>2016</year>) <volume>351</volume>:<fpage>711</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1126/science.aad2791</pub-id><?supplied-pmid 26912858?><pub-id pub-id-type="pmid">26912858</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>T</given-names></name><name><surname>Krovi</surname><given-names>HS</given-names></name><name><surname>Landry</surname><given-names>LG</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>N</given-names></name><name><surname>Hohenstein</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Development of T cell lines sensitive to antigen stimulation</article-title>. <source>J Immunol Methods.</source> (<year>2018</year>) <volume>462</volume>:<fpage>65</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jim.2018.08.011</pub-id><?supplied-pmid 30165064?><pub-id pub-id-type="pmid">30165064</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinilla</surname><given-names>C</given-names></name><name><surname>Appel</surname><given-names>JR</given-names></name><name><surname>Judkowski</surname><given-names>V</given-names></name><name><surname>Houghten</surname><given-names>RA</given-names></name></person-group>
<article-title>Identification of B cell and T cell epitopes using synthetic peptide combinatorial libraries</article-title>. <source>Curr Protoc Immunol.</source> (<year>2012</year>) <volume>9</volume>:<fpage>9.5.1</fpage>&#8211;<lpage>9.5.16</lpage>. <pub-id pub-id-type="doi">10.1002/0471142735.im0905s99</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falta</surname><given-names>MT</given-names></name><name><surname>Pinilla</surname><given-names>C</given-names></name><name><surname>Mack</surname><given-names>DG</given-names></name><name><surname>Tinega</surname><given-names>AN</given-names></name><name><surname>Crawford</surname><given-names>F</given-names></name><name><surname>Giulianotti</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Identification of beryllium-dependent peptides recognized by CD4+ T cells in chronic beryllium disease</article-title>. <source>J Exp Med.</source> (<year>2013</year>) <volume>210</volume>:<fpage>1403</fpage>&#8211;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20122426</pub-id><?supplied-pmid 23797096?><pub-id pub-id-type="pmid">23797096</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>EA</given-names></name><name><surname>Bui</surname><given-names>J</given-names></name><name><surname>Berger</surname><given-names>D</given-names></name><name><surname>Huston</surname><given-names>L</given-names></name><name><surname>Roti</surname><given-names>M</given-names></name><name><surname>Kwok</surname><given-names>WW</given-names></name></person-group>. <article-title>Tetramer-guided epitope mapping reveals broad, individualized repertoires of tetanus toxin-specific CD4+ T cells and suggests HLA-based differences in epitope recognition</article-title>. <source>Int Immunol.</source> (<year>2007</year>) <volume>19</volume>:<fpage>1291</fpage>&#8211;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxm099</pub-id><?supplied-pmid 17906339?><pub-id pub-id-type="pmid">17906339</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velthuis</surname><given-names>JH</given-names></name><name><surname>Unger</surname><given-names>WW</given-names></name><name><surname>Abreu</surname><given-names>JR</given-names></name><name><surname>Duinkerken</surname><given-names>G</given-names></name><name><surname>Franken</surname><given-names>K</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Simultaneous detection of circulating autoreactive CD8+ T-cells specific for different islet cell-associated epitopes using combinatorial MHC multimers</article-title>. <source>Diabetes.</source> (<year>2010</year>) <volume>59</volume>:<fpage>1721</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2337/db09-1486</pub-id><?supplied-pmid 20357361?><pub-id pub-id-type="pmid">20357361</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arif</surname><given-names>S</given-names></name><name><surname>Tree</surname><given-names>TI</given-names></name><name><surname>Astill</surname><given-names>TP</given-names></name><name><surname>Tremble</surname><given-names>JM</given-names></name><name><surname>Bishop</surname><given-names>AJ</given-names></name><name><surname>Dayan</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health</article-title>. <source>J Clin Invest.</source> (<year>2004</year>) <volume>113</volume>:<fpage>451</fpage>&#8211;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1172/JCI19585</pub-id><?supplied-pmid 14755342?><pub-id pub-id-type="pmid">14755342</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>M</given-names></name><name><surname>Kotani</surname><given-names>R</given-names></name><name><surname>Moriyama</surname><given-names>H</given-names></name><name><surname>Yokono</surname><given-names>K</given-names></name><name><surname>Roep</surname><given-names>BO</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name></person-group>. <article-title>Detection of autoreactive T cells in type 1 diabetes using coded autoantigens and an immunoglobulin-free cytokine ELISPOT assay: report from the fourth immunology of diabetes society T cell workshop</article-title>. <source>Ann N Y Acad Sci.</source> (<year>2004</year>) <volume>1037</volume>:<fpage>10</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1337.002</pub-id><?supplied-pmid 15699487?><pub-id pub-id-type="pmid">15699487</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glanville</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Nau</surname><given-names>A</given-names></name><name><surname>Hatton</surname><given-names>O</given-names></name><name><surname>Wagar</surname><given-names>LE</given-names></name><name><surname>Rubelt</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Identifying specificity groups in the T cell receptor repertoire</article-title>. <source>Nature.</source> (<year>2017</year>) <volume>547</volume>:<fpage>94</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nature22976</pub-id><?supplied-pmid 28636589?><pub-id pub-id-type="pmid">28636589</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roep</surname><given-names>BO</given-names></name><name><surname>Wheeler</surname><given-names>DCS</given-names></name><name><surname>Peakman</surname><given-names>M</given-names></name></person-group>. <article-title>Antigen-based immune modulation therapy for type 1 diabetes: the era of precision medicine</article-title>. <source>Lancet Diabetes Endocrinol.</source> (<year>2019</year>) <volume>7</volume>:<fpage>65</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(18)30109-8</pub-id><?supplied-pmid 30528100?><pub-id pub-id-type="pmid">30528100</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>KC</given-names></name><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Auger</surname><given-names>JA</given-names></name><name><surname>Poumian-Ruiz</surname><given-names>E</given-names></name><name><surname>Taylor</surname><given-names>L</given-names></name><name><surname>Donaldson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus</article-title>. <source>N Engl J Med.</source> (<year>2002</year>) <volume>346</volume>:<fpage>1692</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa012864</pub-id><?supplied-pmid 12037148?><pub-id pub-id-type="pmid">12037148</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keymeulen</surname><given-names>B</given-names></name><name><surname>Vandemeulebroucke</surname><given-names>E</given-names></name><name><surname>Ziegler</surname><given-names>AG</given-names></name><name><surname>Mathieu</surname><given-names>C</given-names></name><name><surname>Kaufman</surname><given-names>L</given-names></name><name><surname>Hale</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes</article-title>. <source>N Engl J Med.</source> (<year>2005</year>) <volume>352</volume>:<fpage>2598</fpage>&#8211;<lpage>608</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa043980</pub-id><?supplied-pmid 15972866?><pub-id pub-id-type="pmid">15972866</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherry</surname><given-names>N</given-names></name><name><surname>Hagopian</surname><given-names>W</given-names></name><name><surname>Ludvigsson</surname><given-names>J</given-names></name><name><surname>Jain</surname><given-names>SM</given-names></name><name><surname>Wahlen</surname><given-names>J</given-names></name><name><surname>Ferry</surname><given-names>RJ</given-names><suffix>Jr</suffix></name><etal/></person-group>. <article-title>Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial</article-title>. <source>Lancet.</source> (<year>2011</year>) <volume>378</volume>:<fpage>487</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60931-8</pub-id><?supplied-pmid 21719095?><pub-id pub-id-type="pmid">21719095</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rigby</surname><given-names>MR</given-names></name><name><surname>Harris</surname><given-names>KM</given-names></name><name><surname>Pinckney</surname><given-names>A</given-names></name><name><surname>DiMeglio</surname><given-names>LA</given-names></name><name><surname>Rendell</surname><given-names>MS</given-names></name><name><surname>Felner</surname><given-names>EI</given-names></name><etal/></person-group>. <article-title>Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients</article-title>. <source>J Clin Invest.</source> (<year>2015</year>) <volume>125</volume>:<fpage>3285</fpage>&#8211;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1172/JCI81722</pub-id><?supplied-pmid 26193635?><pub-id pub-id-type="pmid">26193635</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pescovitz</surname><given-names>MD</given-names></name><name><surname>Greenbaum</surname><given-names>CJ</given-names></name><name><surname>Krause-Steinrauf</surname><given-names>H</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name><name><surname>Gitelman</surname><given-names>SE</given-names></name><name><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Rituximab, B-lymphocyte depletion, and preservation of beta-cell function</article-title>. <source>N Engl J Med.</source> (<year>2009</year>) <volume>361</volume>:<fpage>2143</fpage>&#8211;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0904452</pub-id><?supplied-pmid 19940299?><pub-id pub-id-type="pmid">19940299</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orban</surname><given-names>T</given-names></name><name><surname>Bundy</surname><given-names>B</given-names></name><name><surname>Becker</surname><given-names>DJ</given-names></name><name><surname>DiMeglio</surname><given-names>LA</given-names></name><name><surname>Gitelman</surname><given-names>SE</given-names></name><name><surname>Goland</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet.</source> (<year>2011</year>) <volume>378</volume>:<fpage>412</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60886-6</pub-id><?supplied-pmid 21719096?><pub-id pub-id-type="pmid">21719096</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haller</surname><given-names>MJ</given-names></name><name><surname>Schatz</surname><given-names>DA</given-names></name><name><surname>Skyler</surname><given-names>JS</given-names></name><name><surname>Krischer</surname><given-names>JP</given-names></name><name><surname>Bundy</surname><given-names>BN</given-names></name><name><surname>Miller</surname><given-names>JL</given-names></name><etal/></person-group>. <article-title>Low-Dose Anti-Thymocyte Globulin (ATG) preserves beta-cell function and improves HbA1c in new-onset type 1 diabetes</article-title>. <source>Diabetes Care.</source> (<year>2018</year>) <volume>41</volume>:<fpage>1917</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.2337/dc18-0494</pub-id><?supplied-pmid 30012675?><pub-id pub-id-type="pmid">30012675</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michels</surname><given-names>AW</given-names></name><name><surname>Ostrov</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Fuse</surname><given-names>M</given-names></name><name><surname>McDaniel</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation</article-title>. <source>J Immunol.</source> (<year>2011</year>) <volume>187</volume>:<fpage>5921</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1100746</pub-id><?supplied-pmid 22043012?><pub-id pub-id-type="pmid">22043012</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostrov</surname><given-names>DA</given-names></name><name><surname>Alkanani</surname><given-names>A</given-names></name><name><surname>McDaniel</surname><given-names>KA</given-names></name><name><surname>Case</surname><given-names>S</given-names></name><name><surname>Baschal</surname><given-names>EE</given-names></name><name><surname>Pyle</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes</article-title>. <source>J Clin Invest.</source> (<year>2018</year>) <volume>128</volume>:<fpage>1888</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1172/JCI97739</pub-id><?supplied-pmid 29438107?><pub-id pub-id-type="pmid">29438107</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mah</surname><given-names>GT</given-names></name><name><surname>Tejani</surname><given-names>AM</given-names></name><name><surname>Musini</surname><given-names>VM</given-names></name></person-group>
<article-title>Methyldopa for primary hypertension</article-title>. <source>Cochrane Database Syst Rev.</source> (<year>2009</year>) <volume>4</volume>:<fpage>Cd003893</fpage>
<pub-id pub-id-type="doi">10.1002/14651858.CD003893.pub2</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>S</given-names></name><name><surname>Santamaria</surname><given-names>P</given-names></name></person-group>. <article-title>MHC class II polymorphisms, autoreactive T-cells, and autoimmunity</article-title>. <source>Front Immunol.</source> (<year>2013</year>) <volume>4</volume>:<fpage>321</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2013.00321</pub-id><?supplied-pmid 24133494?><pub-id pub-id-type="pmid">24133494</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dendrou</surname><given-names>CA</given-names></name><name><surname>Petersen</surname><given-names>J</given-names></name><name><surname>Rossjohn</surname><given-names>J</given-names></name><name><surname>Fugger</surname><given-names>L</given-names></name></person-group>. <article-title>HLA variation and disease</article-title>. <source>Nat Rev Immunol.</source> (<year>2018</year>) <volume>18</volume>:<fpage>325</fpage>&#8211;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2017.143</pub-id><?supplied-pmid 29292391?><pub-id pub-id-type="pmid">29292391</pub-id></mixed-citation></ref></ref-list></back></article>